| D12E |
UL51 |
SNP |
Human betaherpesvirus 5 |
1.40 |
No resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| E17del |
UL51 |
in/del |
Human betaherpesvirus 5 |
1.30 |
No resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| P91S |
UL51 |
SNP |
Human betaherpesvirus 5 |
2.10 |
Low level resistance
|
Details |
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017) |
| A95V |
UL51 |
SNP |
Human betaherpesvirus 5 |
13.80 |
High level resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| V113L |
UL51 |
SNP |
Human betaherpesvirus 5 |
1.50 |
No resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| C25F |
UL56 |
SNP |
Human betaherpesvirus 5 |
5.40 |
High level resistance
|
Details |
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018) |
| S229F |
UL56 |
SNP |
Human betaherpesvirus 5 |
1.80 |
No resistance
|
Details |
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017) |
| V231A |
UL56 |
SNP |
Human betaherpesvirus 5 |
2.10 |
Low level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| V231L |
UL56 |
SNP |
Human betaherpesvirus 5 |
5.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| N232Y |
UL56 |
SNP |
Human betaherpesvirus 5 |
17.00 |
High level resistance
|
Details |
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017) |
| V236A |
UL56 |
SNP |
Human betaherpesvirus 5 |
2.90 |
Low level resistance
|
Details |
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018) |
| V236L |
UL56 |
SNP |
Human betaherpesvirus 5 |
14.00 |
High level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| V236M |
UL56 |
SNP |
Human betaherpesvirus 5 |
45.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| E237D |
UL56 |
SNP |
Human betaherpesvirus 5 |
10.00 |
High level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| L241P |
UL56 |
SNP |
Human betaherpesvirus 5 |
218.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| T244K |
UL56 |
SNP |
Human betaherpesvirus 5 |
3.30 |
Intermediate level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| L254F |
UL56 |
SNP |
Human betaherpesvirus 5 |
3.20 |
Intermediate level resistance
|
Details |
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017) |
| L257F |
UL56 |
SNP |
Human betaherpesvirus 5 |
8.60 |
High level resistance
|
Details |
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017) |
| L257I |
UL56 |
SNP |
Human betaherpesvirus 5 |
4.90 |
Intermediate level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| K258E |
UL56 |
SNP |
Human betaherpesvirus 5 |
14.00 |
High level resistance
|
Details |
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017) |
| F261C |
UL56 |
SNP |
Human betaherpesvirus 5 |
4.40 |
Intermediate level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| F261L |
UL56 |
SNP |
Human betaherpesvirus 5 |
2.80 |
Low level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| Y321C |
UL56 |
SNP |
Human betaherpesvirus 5 |
4.60 |
Intermediate level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| C325F |
UL56 |
SNP |
Human betaherpesvirus 5 |
3000.00 |
High level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| C325R |
UL56 |
SNP |
Human betaherpesvirus 5 |
3000.00 |
High level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| C325Y |
UL56 |
SNP |
Human betaherpesvirus 5 |
8796.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| C325W |
UL56 |
SNP |
Human betaherpesvirus 5 |
9300.00 |
High level resistance
|
Details |
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018) |
| L328V |
UL56 |
SNP |
Human betaherpesvirus 5 |
1.90 |
No resistance
|
Details |
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018) |
| M329T |
UL56 |
SNP |
Human betaherpesvirus 5 |
4.40 |
Intermediate level resistance
|
Details |
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015) |
| F345L |
UL56 |
SNP |
Human betaherpesvirus 5 |
0.95-1.03 |
Range of values of No resistance
|
Details |
Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022) |
| A365S |
UL56 |
SNP |
Human betaherpesvirus 5 |
2.00 |
Low level resistance
|
Details |
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018) |
| N368D |
UL56 |
SNP |
Human betaherpesvirus 5 |
2.00 |
Low level resistance
|
Details |
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017) |
| R369T |
UL56 |
SNP |
Human betaherpesvirus 5 |
52.00 |
High level resistance
|
Details |
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020) |
| R369G |
UL56 |
SNP |
Human betaherpesvirus 5 |
44.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| R369M |
UL56 |
SNP |
Human betaherpesvirus 5 |
13.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| R369S |
UL56 |
SNP |
Human betaherpesvirus 5 |
48.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| R396S |
UL56 |
SNP |
Human betaherpesvirus 5 |
81.00 |
High level resistance
|
Details |
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014) |
| N320H |
UL89 |
SNP |
Human betaherpesvirus 5 |
1.80 |
No resistance
|
Details |
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017) |
| N329S |
UL89 |
SNP |
Human betaherpesvirus 5 |
2.00 |
Low level resistance
|
Details |
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017) |
| D344E |
UL89 |
SNP |
Human betaherpesvirus 5 |
1.80 |
No resistance
|
Details |
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017) |
| T350M |
UL89 |
SNP |
Human betaherpesvirus 5 |
2.80 |
Low level resistance
|
Details |
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017) |
| M359I |
UL89 |
SNP |
Human betaherpesvirus 5 |
1.50 |
No resistance
|
Details |
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020) |
